Literature DB >> 29848582

VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.

Ken Fujii1, Yui Sudaka1, Ayako Takashino1, Kyousuke Kobayashi1, Chikako Kataoka2, Tadaki Suzuki3, Naoko Iwata-Yoshikawa3, Osamu Kotani4, Yasushi Ami5, Hiroyuki Shimizu2, Noriyo Nagata3, Katsumi Mizuta6, Yoko Matsuzaki7, Satoshi Koike8.   

Abstract

Enterovirus 71 (EV71) is a causative agent of hand, foot, and mouth disease and sometimes causes severe or fatal neurological complications. The amino acid at VP1-145 determines the virological characteristics of EV71. Viruses with glutamic acid (E) at VP1-145 (VP1-145E) are virulent in neonatal mice and transgenic mice expressing human scavenger receptor B2, whereas those with glutamine (Q) or glycine (G) are not. However, the contribution of this variation to pathogenesis in humans is not fully understood. We compared the virulence of VP1-145E and VP1-145G viruses of Isehara and C7/Osaka backgrounds in cynomolgus monkeys. VP1-145E, but not VP1-145G, viruses induced neurological symptoms. VP1-145E viruses were frequently detected in the tissues of infected monkeys. VP1-145G viruses were detected less frequently and disappeared quickly. Instead, mutants that had a G-to-E mutation at VP1-145 emerged, suggesting that VP1-145E viruses have a replication advantage in the monkeys. This is consistent with our hypothesis proposed in the accompanying paper (K. Kobayashi, Y. Sudaka, A. Takashino, A. Imura, K. Fujii, and S. Koike, J Virol 92:e00681-18, 2018, https://doi.org/10.1128/JVI.00681-18) that the VP1-145G virus is attenuated due to its adsorption by heparan sulfate. Monkeys infected with both viruses produced neutralizing antibodies before the onset of the disease. Interestingly, VP1-145E viruses were more resistant to neutralizing antibodies than VP1-145G viruses in vitro A small amount of neutralizing antibody raised in the early phase of infection may not be sufficient to block the dissemination of VP1-145E viruses. The different resistance of the VP1-145 variants to neutralizing antibodies may be one of the reasons for the difference in virulence.IMPORTANCE The contribution of VP1-145 variants in humans is not fully understood. In some studies, VP1-145G/Q viruses were isolated more frequently from severely affected patients than from mildly affected patients, suggesting that VP1-145G/Q viruses are more virulent. In the accompanying paper (K. Kobayashi, Y. Sudaka, A. Takashino, A. Imura, K. Fujii, and S. Koike, J Virol 92:e00681-18, 2018, https://doi.org/10.1128/JVI.00681-18), we showed that VP1-145E viruses are more virulent than VP1-145G viruses in human SCARB2 transgenic mice. Heparan sulfate acts as a decoy to specifically trap the VP1-145G viruses and leads to abortive infection. Here, we demonstrated that VP1-145G was attenuated in cynomolgus monkeys, suggesting that this hypothesis is also true in a nonhuman primate model. VP1-145E viruses, but not VP1-145G viruses, were highly resistant to neutralizing antibodies. We propose the difference in resistance against neutralizing antibodies as another mechanism of EV71 virulence. In summary, VP1-145 contributes to virulence determination by controlling attachment receptor usage and antibody sensitivity.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  animal models; enterovirus; neutralizing antibodies; pathogenesis

Mesh:

Substances:

Year:  2018        PMID: 29848582      PMCID: PMC6052295          DOI: 10.1128/JVI.00682-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Amino Acid Variation at VP1-145 of Enterovirus 71 Determines Attachment Receptor Usage and Neurovirulence in Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Kyousuke Kobayashi; Yui Sudaka; Ayako Takashino; Ayumi Imura; Ken Fujii; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

2.  Crystal structure of human enterovirus 71.

Authors:  Pavel Plevka; Rushika Perera; Jane Cardosa; Richard J Kuhn; Michael G Rossmann
Journal:  Science       Date:  2012-03-01       Impact factor: 47.728

3.  Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia.

Authors:  P J Mease; H D Ochs; R J Wedgwood
Journal:  N Engl J Med       Date:  1981-05-21       Impact factor: 91.245

Review 4.  Virology, epidemiology, pathogenesis, and control of enterovirus 71.

Authors:  Tom Solomon; Penny Lewthwaite; David Perera; Mary Jane Cardosa; Peter McMinn; Mong How Ooi
Journal:  Lancet Infect Dis       Date:  2010-10-18       Impact factor: 25.071

5.  Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection.

Authors:  I Hashimoto; A Hagiwara
Journal:  Neuropathol Appl Neurobiol       Date:  1982 Mar-Apr       Impact factor: 8.090

6.  Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007.

Authors:  K Mizuta; Y Aoki; A Suto; K Ootani; N Katsushima; T Itagaki; A Ohmi; M Okamoto; H Nishimura; Y Matsuzaki; S Hongo; K Sugawara; H Shimizu; T Ahiko
Journal:  Vaccine       Date:  2009-04-10       Impact factor: 3.641

7.  Isolation of a temperature-sensitive strain of enterovirus 71 with reduced neurovirulence for monkeys.

Authors:  A Hagiwara; T Yoneyama; I Hashimoto
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

8.  The Role of VP1 Amino Acid Residue 145 of Enterovirus 71 in Viral Fitness and Pathogenesis in a Cynomolgus Monkey Model.

Authors:  Chikako Kataoka; Tadaki Suzuki; Osamu Kotani; Naoko Iwata-Yoshikawa; Noriyo Nagata; Yasushi Ami; Takaji Wakita; Yorihiro Nishimura; Hiroyuki Shimizu
Journal:  PLoS Pathog       Date:  2015-07-16       Impact factor: 6.823

9.  Norovirus Escape from Broadly Neutralizing Antibodies Is Limited to Allostery-Like Mechanisms.

Authors:  Abimbola O Kolawole; Hong Q Smith; Sophia A Svoboda; Madeline S Lewis; Michael B Sherman; Gillian C Lynch; B Montgomery Pettitt; Thomas J Smith; Christiane E Wobus
Journal:  mSphere       Date:  2017-10-18       Impact factor: 4.389

10.  Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction.

Authors:  Yorihiro Nishimura; Hyunwook Lee; Susan Hafenstein; Chikako Kataoka; Takaji Wakita; Jeffrey M Bergelson; Hiroyuki Shimizu
Journal:  PLoS Pathog       Date:  2013-07-25       Impact factor: 6.823

View more
  23 in total

1.  Amino Acid Variation at VP1-145 of Enterovirus 71 Determines Attachment Receptor Usage and Neurovirulence in Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Kyousuke Kobayashi; Yui Sudaka; Ayako Takashino; Ayumi Imura; Ken Fujii; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

2.  In Vitro and In Vivo Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN.

Authors:  Tao Meng; Qiang Jia; Sek-Man Wong; Kaw-Bing Chua
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 3.  Recent advances in enterovirus A71 pathogenesis: a focus on fatal human enterovirus A71 infection.

Authors:  Jingjun Xing; Ke Wang; Geng Wang; Na Li; Yanru Zhang
Journal:  Arch Virol       Date:  2022-09-29       Impact factor: 2.685

4.  SLC35B2 Acts in a Dual Role in the Host Sulfation Required for EV71 Infection.

Authors:  Dong Guo; Xinghai Yu; Dan Wang; Zhifei Li; Yu Zhou; Guodong Xu; Bing Yuan; Yali Qin; Mingzhou Chen
Journal:  J Virol       Date:  2022-04-14       Impact factor: 6.549

5.  Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Ayumi Imura; Yui Sudaka; Ayako Takashino; Kanami Tamura; Kyousuke Kobayashi; Noriyo Nagata; Hidekazu Nishimura; Katsumi Mizuta; Satoshi Koike
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

6.  Virulence of Enterovirus A71 Fluctuates Depending on the Phylogenetic Clade Formed in the Epidemic Year and Epidemic Region.

Authors:  Kyousuke Kobayashi; Hidekazu Nishimura; Katsumi Mizuta; Tomoha Nishizawa; Son T Chu; Hiroshi Ichimura; Satoshi Koike
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103

7.  Severity of enterovirus A71 infection in a human SCARB2 knock-in mouse model is dependent on infectious strain and route.

Authors:  Junping Zhu; Ning Chen; Shuya Zhou; Kai Zheng; Lin Sun; Yuxiao Zhang; Lina Cao; Xiaoyan Zhang; Qiaoyan Xiang; Zhiyun Chen; Chenfei Wang; Changfa Fan; Qiushui He
Journal:  Emerg Microbes Infect       Date:  2018-12-05       Impact factor: 7.163

Review 8.  Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?

Authors:  Valeria Cagno; Eirini D Tseligka; Samuel T Jones; Caroline Tapparel
Journal:  Viruses       Date:  2019-07-01       Impact factor: 5.048

Review 9.  Antivirals and vaccines for Enterovirus A71.

Authors:  Jing-Yi Lin; Yu-An Kung; Shin-Ru Shih
Journal:  J Biomed Sci       Date:  2019-09-03       Impact factor: 8.410

10.  A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism.

Authors:  Eirini D Tseligka; Komla Sobo; Luc Stoppini; Valeria Cagno; Fabien Abdul; Isabelle Piuz; Pascal Meylan; Song Huang; Samuel Constant; Caroline Tapparel
Journal:  PLoS Pathog       Date:  2018-08-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.